Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (Nature, (2018), 554, 7691, (189-194), 10.1038/nature25475)

David M. Hyman, Sarina A. Piha-Paul, Helen Won, Jordi Rodon, Cristina Saura, Geoffrey I. Shapiro, Dejan Juric, David I. Quinn, Victor Moreno, Bernard Doger, Ingrid A. Mayer, Valentina Boni, Emiliano Calvo, Sherene Loi, Albert C. Lockhart, Joseph P. Erinjeri, Maurizio Scaltriti, Gary A. Ulaner, Juber Patel, Jiabin TangHannah Beer, S. Duygu Selcuklu, Aphrothiti J. Hanrahan, Nancy Bouvier, Myra Melcer, Rajmohan Murali, Alison M. Schram, Lillian M. Smyth, Komal Jhaveri, Bob T. Li, Alexander Drilon, James J. Harding, Gopa Iyer, Barry S. Taylor, Michael F. Berger, Richard E. Cutler, Feng Xu, Anna Butturini, Lisa D. Eli, Grace Mann, Cynthia Farrell, Alshad S. Lalani, Richard P. Bryce, Carlos L. Arteaga, Funda Meric-Bernstam, José Baselga, David B. Solit

Research output: Contribution to journalComment/debatepeer-review

7 Scopus citations

Abstract

The ‘Competing interests’ statement of this Article has been updated; please see the accompanying Amendment. The original Article has not been corrected online.

Original languageEnglish (US)
Pages (from-to)E11-E12
JournalNature
Volume566
Issue number7745
DOIs
StatePublished - Feb 28 2019
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (Nature, (2018), 554, 7691, (189-194), 10.1038/nature25475)'. Together they form a unique fingerprint.

Cite this